Skip to content

A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab (NAVIGATE)

A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab (NAVIGATE). (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis (scaly skin rash) who had inadequate response to ustekinumab. Double-blind Study to Evaluate the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab. Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab. Based on the results of a previous phase 1 study of guselkumab, a phase 2 study was conducted to test various doses of guselkumab, while also comparing it with another treatment currently used for psoriasis, adalimumab.

A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab (NAVIGATE) 2A study of guselkumab in participants with moderate to severe plaque-type psoriasis and an inadequate response to ustekinumab (NAVIGATE), NCT02203032. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. In a phase 2 study of 404 participants, PASI 75 scores were assessed at 12 weeks with the SC administration of AIN457 in participants with moderate to severe psoriasis at 3 dosing regimens: (1) a single dose of 150 mg (week 1), (2) monthly doses of 150 mg (weeks 1, 5, and 9), (3) early loading doses of 150 mg (weeks 1, 2, 3, 5, and 9), as compared to placebo.

The discovery of the biological functions of the interleukin-23/-17 axis led to the identification of IL-23 and IL-17 as important participants in the pathogenesis of several immune-mediated diseases. A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab Status: Active, not recruiting Condition: Psoriasis. Moderate Psoriasis Therapeutics Clinical Trials Market, Global, Clinical Trials by AbbVie Inc. Efficacy of ixekizumab in participants with moderate to severe chronic plaque psoriasis.

A Review Of Biologic Therapies Targeting Il-23 And Il-17 For Use In Moderate-to-severe Plaque Psoriasis(pdf)

Drugs targeting IL-23 include BI-655066, briakinumab, guselkumab, tildrakizumab, and ustekinumab. While many of these have shown safety and good efficacy in clinical trials of moderate-to-severe plaque psoriasis, long-term safety is still to be established. A study of guselkumab in participants with moderate to severe plaque-type psoriasis and an inadequate response to ustekinumab (NAVIGATE), NCT02203032. We report two studies of ixekizumab compared with placebo or etanercept to assess the safety and efficacy of specifically targeting interleukin 17A in patients with widespread moderate-to-severe psoriasis. Navigation. A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment. Research Studies alabama – Find and Join Paid Research Studies in alabama. Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY). BI655066 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment. Interventions: Drug: BI 655066; Drug: placebo to ustekinumab; Drug: USTEKINUMAB; BI655066 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment. 12-Week Study of DS-8500a in Subjects With Type 2 Diabetes Mellitus on Metformin. A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT). BI655066 in Moderate to Severe Plaque Psoriasis With Randomized Withdrawal and Re-treatment. A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT).

Therapeutic Targeting Of Il-17 And Il-23 Cytokines In Immune-mediated Diseases